
Annual report 2024
added 01-24-2026
GlaxoSmithKline plc EPS Ratio 2011-2026 | GSK
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio GlaxoSmithKline plc
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 0.876 | 1.16 | 0.939 | 0.737 | 0.314 | 0.188 | 1.74 | - | - | - | - |
All numbers in GBP currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.74 | 0.188 | 0.85 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-15.4 | - | 2.43 % | $ 254 M | ||
|
Adagene
ADAG
|
-0.59 | $ 2.62 | 28.82 % | $ 147 M | ||
|
Acorda Therapeutics
ACOR
|
-204 | - | -24.86 % | $ 820 K | ||
|
Aeterna Zentaris
AEZS
|
-0.07 | - | 5.93 % | $ 314 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-0.53 | $ 3.51 | 7.34 % | $ 8.45 B | ||
|
AgeX Therapeutics
AGE
|
-13.7 | - | -10.17 % | $ 12.2 K | ||
|
Grifols, S.A.
GRFS
|
0.28 | $ 9.25 | 1.49 % | $ 6.83 B | ||
|
Biophytis SA
BPTS
|
-0.26 | - | -13.47 % | $ 169 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-24.9 | - | - | $ 1.01 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
3.29 | $ 25.92 | -0.86 % | $ 1.26 B | ||
|
Midatech Pharma plc
MTP
|
-31 | - | -18.52 % | $ 27.3 M | ||
|
Akero Therapeutics
AKRO
|
-3.75 | - | - | $ 3.67 B | ||
|
Galapagos NV
GLPG
|
-1.58 | $ 34.61 | 0.61 % | $ 2.69 B | ||
|
Ultragenyx Pharmaceutical
RARE
|
-6.29 | $ 24.45 | 4.49 % | $ 2.21 B | ||
|
Aptose Biosciences
APTO
|
-36.4 | - | -45.71 % | $ 1.2 M | ||
|
Aravive
ARAV
|
-2.1 | - | -13.39 % | $ 1.45 M | ||
|
Athira Pharma
ATHA
|
-2.52 | - | - | $ 269 M | ||
|
Akouos
AKUS
|
-2.52 | - | 0.23 % | $ 488 M | ||
|
AVROBIO
AVRO
|
0.27 | - | 1083.1 % | $ 745 M | ||
|
BioLineRx Ltd.
BLRX
|
-0.12 | $ 3.1 | 4.49 % | $ 908 M | ||
|
Applied Molecular Transport
AMTI
|
-3.25 | - | - | $ 10.1 M | ||
|
BioNTech SE
BNTX
|
42.2 | $ 116.27 | -1.86 % | $ 27.2 B | ||
|
Ascendis Pharma A/S
ASND
|
-8.28 | $ 235.41 | 2.95 % | $ 5 B | ||
|
BioXcel Therapeutics
BTAI
|
-23.5 | $ 1.84 | 1.66 % | $ 4.66 M | ||
|
Burford Capital Limited
BUR
|
75.3 | $ 9.74 | -1.37 % | $ 1.55 B | ||
|
ARCA biopharma
ABIO
|
-3.87 | - | 1052.0 % | $ 415 M | ||
|
Aytu BioScience
AYTU
|
-2.16 | $ 2.66 | -1.85 % | $ 16.7 M | ||
|
Acasti Pharma
ACST
|
-0.79 | - | 4.01 % | $ 150 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
-0.01 | $ 67.49 | -3.02 % | $ 9.03 B | ||
|
Brickell Biotech
BBI
|
-1.06 | - | -5.38 % | $ 6.06 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-0.01 | $ 4.51 | 8.41 % | $ 9.81 B | ||
|
BeiGene, Ltd.
BGNE
|
-0.47 | - | 0.49 % | $ 251 B | ||
|
Ayala Pharmaceuticals
AYLA
|
-2.46 | - | - | $ 7.46 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-0.09 | - | -15.15 % | $ 60.3 M | ||
|
AIkido Pharma
AIKI
|
-2.38 | - | 1.93 % | $ 17.4 M | ||
|
Albireo Pharma
ALBO
|
-1.77 | - | -0.23 % | $ 916 M | ||
|
CureVac N.V.
CVAC
|
-2.21 | - | - | $ 867 M | ||
|
Acer Therapeutics
ACER
|
-1.66 | - | 2.71 % | $ 14 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
-0.81 | - | -9.72 % | $ 5.89 M | ||
|
Alpine Immune Sciences
ALPN
|
-1.73 | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
-11.7 | - | 4.14 % | $ 49.1 M | ||
|
Coherus BioSciences
CHRS
|
-2.53 | $ 2.04 | 28.3 % | $ 192 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-10.7 | - | -11.43 % | $ 502 K | ||
|
Biogen
BIIB
|
11.2 | $ 171.89 | -1.1 % | $ 25 B | ||
|
Bio-Path Holdings
BPTH
|
-33.6 | - | - | $ 100 K | ||
|
BioVie
BIVI
|
-12.1 | $ 1.2 | -3.7 % | $ 1.77 M |